• / Free eNewsletters & Magazine
  • / My Account
Home>China charges foreign investigators linked to Glaxo case

Related Content

  1. Videos
  2. Articles
  1. Reasons to Be Bullish on Emerging Markets

    Concerns about Chinese growth, Russia, and global liquidity have driven the prices of several quality stocks to appropriate buying levels, says Oppenheimer manager Justin Leverenz.

  2. Chinese Real Estate a Warning Sign for Commodities

    Sluggishness in the country's real estate sector doesn't bode well for the broader commodities market.

  3. Danoff, Davis, Lynch: Stock-Picking Ahead of the Crowd

    The past Morningstar Manager of the Year winners favor credit card firms, split views on Facebook, address China's importance, extol executives' foresight for future growth and disruption, and much more in this panel presentation at the Morningstar Investment Conference.

  4. Reasons to Increase Your Stake in China

    BaoCap's Kevin Carter says there's no imminent landing--hard or soft--in China , and with the country's 35% contribution to global GDP growth, investors should up Chinese exposure in the consumer and tech sectors.

China charges foreign investigators linked to Glaxo case

China charges foreign investigators linked to Glaxo case


LOS ANGELES (MarketWatch) -- China is charging two Westerners working as private investigators in the country with illegally amassing information on Chinese citizens, Chinese state media said Monday. British national Peter Humphrey and his U.S. wife Yu Yingzeng, both of whom worked for GlaxoSmithKline PLC (UK:GSK)(GSK) to investigate a security breach at the company, were alleged of wrongdoing in charges filed with Shanghai Number One Intermediate People's Court, the official Xinhua News Agency reported. Reuters reported that the couple will go on trial Aug. 7. According to the Xinhua report, the couple illicitly paid for personal information in the course of running their business, which Glaxo paid to investigate a former employee suspected of sending anonymous emails that included allegations of bribery at the British pharmaceutical company.

-Michael Kitchen; 415-439-6400; AskNewswires@dowjones.com


Subscribe to WSJ: http://online.wsj.com?mod=djnwires


(END) Dow Jones Newswires

07-13-14 2351ET

Copyright (c) 2014 Dow Jones & Company, Inc.

blog comments powered by Disqus
Upcoming Events

©2014 Morningstar Advisor. All right reserved.